{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:45:16Z","timestamp":1780681516554,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13518"],"award-info":[{"award-number":["13518"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04306-1","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:27:10Z","timestamp":1769491630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal genetic feeder cell-expanded and engineered NK cell products are composed of CD56bright and CD56dim NK cells"],"prefix":"10.1007","volume":"75","author":[{"given":"Els P.","family":"van Hees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cilia R.","family":"Pothast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"Pool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Frederik","family":"Falkenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine E.","family":"Melsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"3","key":"4306_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J et al (2024) Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med 30(3):772\u2013784","journal-title":"Nat Med"},{"issue":"6","key":"4306_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553","journal-title":"N Engl J Med"},{"issue":"2","key":"4306_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M et al (2018) Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520\u2013531","journal-title":"Leukemia"},{"key":"4306_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003715","author":"LT Morton","year":"2022","unstructured":"Morton LT, Wachsmann TLA, Meeuwsen MH, Wouters AK, Remst DFG, van Loenen MM et al (2022) T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003715","journal-title":"J Immunother Cancer"},{"key":"4306_CR5","doi-asserted-by":"publisher","first-page":"1368290","DOI":"10.3389\/fimmu.2024.1368290","volume":"15","author":"EP van Hees","year":"2024","unstructured":"van Hees EP, Morton LT, Remst DFG, Wouters AK, den Van Eynde A, Falkenburg JHF et al (2024) Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence. Front Immunol 15:1368290","journal-title":"Front Immunol"},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368","journal-title":"Front Immunol"},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4939-3684-7_15","volume":"1441","author":"SS Somanchi","year":"2016","unstructured":"Somanchi SS, Lee DA (2016) Ex vivo expansion of human NK cells using K562 engineered to express membrane bound IL21. Methods Mol Biol 1441:175\u2013193","journal-title":"Methods Mol Biol"},{"issue":"8","key":"4306_CR8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1158\/1078-0432.CCR-12-1243","volume":"19","author":"Y Liu","year":"2013","unstructured":"Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ et al (2013) Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res 19(8):2132\u20132143","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4306_CR9","doi-asserted-by":"publisher","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL et al (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7(1):e30264","journal-title":"PLoS ONE"},{"issue":"1","key":"4306_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, Ozkazanc D, Kucerova L et al (2022) Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol 15(1):164","journal-title":"J Hematol Oncol"},{"key":"4306_CR11","doi-asserted-by":"publisher","first-page":"626098","DOI":"10.3389\/fimmu.2021.626098","volume":"12","author":"E Liu","year":"2021","unstructured":"Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M et al (2021) GMP-compliant universal antigen presenting cells (uAPC) promote the metabolic fitness and antitumor activity of armored cord blood CAR-NK cells. Front Immunol 12:626098","journal-title":"Front Immunol"},{"key":"4306_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050451","author":"A Maia","year":"2024","unstructured":"Maia A, Tarannum M, Lerias JR, Piccinelli S, Borrego LM, Maeurer M et al (2024) Building a better defense: expanding and improving natural killer cells for adoptive cell therapy. Cells. https:\/\/doi.org\/10.3390\/cells13050451","journal-title":"Cells"},{"key":"4306_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS, Malarkannan S (2018) Natural killer cells: development, maturation, and clinical utilization. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.01869","journal-title":"Front Immunol"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","volume":"8","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Jawdat D, Madrigal JA, Saudemont A (2017) Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol 8:329","journal-title":"Front Immunol"},{"issue":"11","key":"4306_CR15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633\u2013640","journal-title":"Trends Immunol"},{"issue":"10","key":"4306_CR16","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","volume":"97","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97(10):3146\u20133151","journal-title":"Blood"},{"issue":"11","key":"4306_CR17","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat C, Long EO, Ljunggren HG, Bryceson YT (2010) Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115(11):2167\u20132176","journal-title":"Blood"},{"issue":"11","key":"4306_CR18","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","volume":"127","author":"JA Wagner","year":"2017","unstructured":"Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW et al (2017) CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest 127(11):4042\u20134058","journal-title":"J Clin Invest"},{"key":"4306_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010205","author":"ML Guevara Lopez","year":"2025","unstructured":"Guevara Lopez ML, Gebo A, Parodi M, Persano S, Maus-Conn J, Mingari MC et al (2025) CD56(bright) cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010205","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4306_CR20","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2326-6066.CIR-18-0144","volume":"6","author":"SM Poznanski","year":"2018","unstructured":"Poznanski SM, Nham T, Chew MV, Lee AJ, Hammill JA, Fan IY et al (2018) Expanded CD56(superbright)CD16(+) NK cells from ovarian cancer patients are cytotoxic against autologous tumor in a patient-derived xenograft murine model. Cancer Immunol Res 6(10):1174\u20131185","journal-title":"Cancer Immunol Res"},{"key":"4306_CR21","doi-asserted-by":"publisher","first-page":"765705","DOI":"10.3389\/fimmu.2021.765705","volume":"12","author":"SA Barnes","year":"2021","unstructured":"Barnes SA, Trew I, de Jong E, Foley B (2021) Making a killer: selecting the optimal natural killer cells for improved immunotherapies. Front Immunol 12:765705","journal-title":"Front Immunol"},{"issue":"8","key":"4306_CR22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.celrep.2019.10.058","volume":"29","author":"A Pfefferle","year":"2019","unstructured":"Pfefferle A, Jacobs B, Netskar H, Ask EH, Lorenz S, Clancy T et al (2019) Intra-lineage plasticity and functional reprogramming maintain natural killer cell repertoire diversity. Cell Rep 29(8):2284\u20132294","journal-title":"Cell Rep"},{"key":"4306_CR23","first-page":"1","volume":"29","author":"JR Caporale","year":"2023","unstructured":"Caporale JR, Lee DA (2023) Attack of the clones: an NK cell origins story. Mol Ther 29:1\u20133","journal-title":"Mol Ther"},{"issue":"8","key":"4306_CR24","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet L, Melsen JE, Escaliere B, Basurto-Lozada D, Bhandoola A, Bjorkstrom NK et al (2024) High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol 25(8):1474\u20131488","journal-title":"Nat Immunol"},{"key":"4306_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fimmu.2018.00150","volume":"9","author":"NAP Lieberman","year":"2018","unstructured":"Lieberman NAP, DeGolier K, Haberthur K, Chinn H, Moyes KW, Bouchlaka MN et al (2018) An uncoupling of canonical phenotypic markers and functional potency of ex vivo-expanded natural killer cells. Front Immunol 9:150","journal-title":"Front Immunol"},{"key":"4306_CR26","first-page":"74","volume":"28","author":"DSJ Allan","year":"2023","unstructured":"Allan DSJ, Wu C, Mortlock RD, Chakraborty M, Rezvani K, Davidson-Moncada JK et al (2023) Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populations. Mol Ther 28:74\u201387","journal-title":"Mol Ther"},{"issue":"1","key":"4306_CR27","doi-asserted-by":"publisher","first-page":"103065","DOI":"10.1016\/j.transci.2021.103065","volume":"60","author":"RJ Golden","year":"2021","unstructured":"Golden RJ, Fesnak AD (2021) Clinical development of natural killer cells expressing chimeric antigen receptors. Transfus Apher Sci 60(1):103065","journal-title":"Transfus Apher Sci"},{"issue":"10","key":"4306_CR28","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","volume":"129","author":"L Jahn","year":"2017","unstructured":"Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T et al (2017) TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood 129(10):1284\u20131295","journal-title":"Blood"},{"issue":"3","key":"4306_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","volume":"37","author":"BA Nijmeijer","year":"2009","unstructured":"Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D et al (2009) Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 37(3):376\u2013385","journal-title":"Exp Hematol"},{"key":"4306_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3389\/fimmu.2018.01829","volume":"9","author":"JE Melsen","year":"2018","unstructured":"Melsen JE, Lugthart G, Vervat C, Kielbasa SM, van der Zeeuw SAJ, Buermans HPJ et al (2018) Human Bone Marrow-Resident Natural Killer Cells Have a Unique Transcriptional Profile and Resemble Resident Memory CD8(+) T Cells. Front Immunol 9:1829","journal-title":"Front Immunol"},{"issue":"4","key":"4306_CR31","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2567.2007.02675.x","volume":"122","author":"K Wendt","year":"2007","unstructured":"Wendt K, Wilk E, Buyny S, Schmidt RE, Jacobs R (2007) Interleukin-21 differentially affects human natural killer cell subsets. Immunology 122(4):486\u2013495","journal-title":"Immunology"},{"issue":"3","key":"4306_CR32","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s10753-014-0082-0","volume":"38","author":"S Navabi","year":"2015","unstructured":"Navabi S, Doroudchi M, Tashnizi AH, Habibagahi M (2015) Natural killer cell functional activity after 4-1BB costimulation. Inflammation 38(3):1181\u20131190","journal-title":"Inflammation"},{"issue":"8","key":"4306_CR33","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","volume":"25","author":"H Netskar","year":"2024","unstructured":"Netskar H, Pfefferle A, Goodridge JP, Sohlberg E, Dufva O, Teichmann SA et al (2024) Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat Immunol 25(8):1445\u20131459","journal-title":"Nat Immunol"},{"issue":"1","key":"4306_CR34","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A et al (2024) CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun 15(1):8439","journal-title":"Nat Commun"},{"issue":"13","key":"4306_CR35","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","volume":"27","author":"LN Kerbauy","year":"2021","unstructured":"Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M et al (2021) Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood-derived NK cells facilitates CAR-like responses against CD30(+) malignancies. Clin Cancer Res 27(13):3744\u20133756","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4306_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","volume":"9","author":"MK Becker-Hapak","year":"2021","unstructured":"Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM et al (2021) A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy. Cancer Immunol Res 9(9):1071\u20131087","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4306_CR37","doi-asserted-by":"publisher","first-page":"2348254","DOI":"10.1080\/2162402X.2024.2348254","volume":"13","author":"ND Marin","year":"2024","unstructured":"Marin ND, Becker-Hapak M, Song WM, Alayo QA, Marsala L, Sonnek N et al (2024) Memory-like differentiation enhances NK cell responses against colorectal cancer. Oncoimmunology 13(1):2348254","journal-title":"Oncoimmunology"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04306-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04306-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:27:11Z","timestamp":1769491631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04306-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04306-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}